Safety Study of Multiple Peptide Vaccine to Esophageal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

June 30, 2008

Conditions
Esophageal Cancer
Interventions
BIOLOGICAL

LY6K, VEGFR1, VEGFR2

1 mg/body every two week with GM-CSF, 4 cycles

Trial Locations (1)

135-8550

Takuya Takayama M.D.Ph.D, Tokyo

All Listed Sponsors
collaborator

Human Genome Center, Institute of Medical Science, University of Tokyo

OTHER

lead

Japanese Foundation for Cancer Research

OTHER

NCT00561275 - Safety Study of Multiple Peptide Vaccine to Esophageal Cancer | Biotech Hunter | Biotech Hunter